Jazz Pharmaceuticals PLC (JAZZ) Position Lifted by GRATRY & Co LLC

GRATRY & Co LLC increased its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 121.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,040 shares of the specialty pharmaceutical company’s stock after purchasing an additional 9,350 shares during the period. Jazz Pharmaceuticals PLC makes up 3.3% of GRATRY & Co LLC’s holdings, making the stock its 3rd biggest position. GRATRY & Co LLC’s holdings in Jazz Pharmaceuticals PLC were worth $2,650,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Somerset Trust Co raised its holdings in shares of Jazz Pharmaceuticals PLC by 0.4% during the second quarter. Somerset Trust Co now owns 3,194 shares of the specialty pharmaceutical company’s stock worth $497,000 after purchasing an additional 14 shares during the last quarter. Level Four Advisory Services LLC raised its holdings in shares of Jazz Pharmaceuticals PLC by 0.8% during the first quarter. Level Four Advisory Services LLC now owns 2,729 shares of the specialty pharmaceutical company’s stock worth $389,000 after purchasing an additional 23 shares during the last quarter. World Asset Management Inc raised its holdings in shares of Jazz Pharmaceuticals PLC by 1.9% during the second quarter. World Asset Management Inc now owns 1,441 shares of the specialty pharmaceutical company’s stock worth $224,000 after purchasing an additional 27 shares during the last quarter. Profund Advisors LLC raised its holdings in shares of Jazz Pharmaceuticals PLC by 1.3% during the second quarter. Profund Advisors LLC now owns 2,915 shares of the specialty pharmaceutical company’s stock worth $453,000 after purchasing an additional 38 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. raised its holdings in shares of Jazz Pharmaceuticals PLC by 0.8% during the first quarter. Nomura Asset Management Co. Ltd. now owns 6,550 shares of the specialty pharmaceutical company’s stock worth $951,000 after purchasing an additional 50 shares during the last quarter. 88.34% of the stock is owned by hedge funds and other institutional investors.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded down 1.239% during mid-day trading on Friday, hitting $139.845. 214,415 shares of the stock traded hands. Jazz Pharmaceuticals PLC has a 12-month low of $95.80 and a 12-month high of $163.75. The firm’s 50 day moving average price is $148.56 and its 200 day moving average price is $151.50. The firm has a market cap of $8.40 billion, a price-to-earnings ratio of 21.541 and a beta of 1.05.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.85 by ($0.13). The company had revenue of $394.39 million during the quarter, compared to analysts’ expectations of $410.83 million. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.67 EPS. On average, equities research analysts predict that Jazz Pharmaceuticals PLC will post $10.88 EPS for the current fiscal year.

In other news, EVP Michael Patrick Miller sold 200 shares of the stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $154.97, for a total value of $30,994.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Suzanne Sawochka Hooper sold 4,580 shares of the stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $160.00, for a total transaction of $732,800.00. Following the completion of the transaction, the executive vice president now owns 32,322 shares of the company’s stock, valued at approximately $5,171,520. The disclosure for this sale can be found here. Insiders sold a total of 9,297 shares of company stock valued at $1,429,417 in the last quarter. Insiders own 4.30% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://sportsperspectives.com/2017/10/13/jazz-pharmaceuticals-plc-jazz-position-lifted-by-gratry-co-llc.html.

JAZZ has been the subject of several recent research reports. Stifel Nicolaus reissued a “buy” rating and set a $190.00 target price on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, August 30th. Cantor Fitzgerald reissued a “buy” rating on shares of Jazz Pharmaceuticals PLC in a report on Tuesday, August 29th. Mizuho cut shares of Jazz Pharmaceuticals PLC from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $162.00 to $150.00 in a report on Tuesday, July 4th. Deutsche Bank AG set a $178.00 target price on shares of Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a report on Monday, July 17th. Finally, Wells Fargo & Company reissued a “buy” rating on shares of Jazz Pharmaceuticals PLC in a report on Tuesday, August 29th. One research analyst has rated the stock with a sell rating, five have given a hold rating and eighteen have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $179.79.

Jazz Pharmaceuticals PLC Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply